Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

CRUK. Bowel cancer incidence statistics. Cancer Research UK. 2017. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence%0Ahttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence#heading-One%250.

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.

PubMed  Google Scholar 

Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.

PubMed  Google Scholar 

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409–24.

CAS  PubMed  Google Scholar 

Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832–41.

PubMed  PubMed Central  Google Scholar 

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.

CAS  PubMed  Google Scholar 

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36:1631–41.

CAS  PubMed  Google Scholar 

Kim M-J, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee J-O, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer. 2012;12:347.

CAS  PubMed  PubMed Central  Google Scholar 

Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, et al. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. Biochem Biophys Res Commun. 2015;458:52–6.

CAS  PubMed  Google Scholar 

Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 2019;20:71–88.

CAS  PubMed  Google Scholar 

Denis JA, Guillerm E, Coulet F, Larsen AK, Lacorte J-M. The role of BEAMing and digital PCR for multiplexed analysis in molecular oncology in the era of next-generation sequencing. Mol Diagn Ther. 2017;21:587–600.

CAS  PubMed  Google Scholar 

Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13:34.

PubMed  PubMed Central  Google Scholar 

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124:345–58.

PubMed  Google Scholar 

Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S. et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015;10a:CD011134.

Google Scholar 

Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS ONE 2017;12:e0171810.

PubMed  PubMed Central  Google Scholar 

Lee JS, Rhee TM, Pietrasz D, Bachet JB, Laurent-Puig P, Kong SY, et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci Rep. 2019;9:1–7.

Google Scholar 

Chae YK, Oh MS. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions. J Thorac Oncol. 2019;14:16–24.

CAS  PubMed  Google Scholar 

Cullinane C, Fleming C, O’Leary DP, Hassan F, Kelly L, O’Sullivan MJ, et al. Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:1–10.

Google Scholar 

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.

PubMed  PubMed Central  Google Scholar 

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.

CAS  PubMed  Google Scholar 

Levy M, Benesova L, Lipska L, Belsanova B, Minarikova P, Veprekova G, et al. Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Res. 2012;32:1621–6.

CAS  PubMed  Google Scholar 

Lee S, Park Y-S, Chang W-J, Choi JY, Lim A, Kim B, et al. Clinical implication of liquid biopsy in colorectal cancer patients treated with metastasectomy. Cancers. 2021;13:2231.

Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, et al. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep. 2017;7:40737.

CAS  PubMed  PubMed Central  Google Scholar 

Lindforss U, Zetterquist H, Papadogiannakis N, Olivecrona H. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res. 2005;25:657–61.

CAS  PubMed  Google Scholar 

Suzuki T, Suzuki T, Yoshimura Y, Yahata M, Yew PY, Nakamura T, et al. Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget. 2020;11:3198–207.

PubMed  PubMed Central  Google Scholar 

Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, et al. MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. 2020;26:183–92.

CAS  PubMed  Google Scholar 

Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol. 2018;144:1741–50.

CAS  PubMed  Google Scholar 

Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial. Clin Cancer Res. 2021;27:5638–46.

Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 2021;18:1–16.

Google Scholar 

Schøler LV, Reinert T, Ørntoft MBW, Kassentoft CG, Arnadøttir SS, Vang S, et al. Clinical implications of monitoring circulating Tumor DNA in patients with colorectal cancer. Clin Cancer Res. 2017;23:5437–45.

PubMed  Google Scholar 

Jones RP, Pugh SA, Graham J, Primrose JN, Barriuso J. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. Eur J Cancer. 2021;144:368–81.

CAS  PubMed  Google Scholar 

Coakley M, Garcia-Murillas I, Turner NC. Molecular residual disease and adjuvant trial design in solid tumors. Clin Cancer Res. 2019;25:6026–34.

CAS  PubMed  Google Scholar 

Dasari A, Grothey A, Kopetz S. Circulating tumor DNA-defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.78.9032.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5:1124–31.

PubMed  PubMed Central  Google Scholar 

Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5:1710–7.

PubMed  PubMed Central  Google Scholar 

Petrelli F, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, et al. Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. A systematic review and meta-analysis. Cancers. 2019;11:1–11.

Google Scholar 

Chen K, Zhao H, Shi Y, Yang F, Wang LT, Kang G, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (Dynamic). Clin Cancer Res. 2019;25:7058–67.

CAS  PubMed  Google Scholar 

Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtroder K, Gogenur M, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol. 2020;14:1670–9.

CAS  PubMed  PubMed Central  Google Scholar 

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:9530–5.

PubMed  PubMed Central  Google Scholar 

Killock D. Personalized MRD assays and therapy? Nat Rev Clin Oncol. 2019;16:593.

CAS  PubMed  Google Scholar 

Leon Arellano M, García-Arranz M, Ruiz R, Olivera R, Magallares S, Olmedillas-Lopez S, et al. A first step to a biomarker of curative surgery in colorectal cancer by liquid biopsy of methylated septin 9 gene. Dis Markers. 2020;2020:9761406.

Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in colorectal cancer patients. Clin Cancer Res. 2021;27:5586–94.

Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA. 2021;118:e2017421118.

Benešová L, Hálková T, Ptáčková R, Semyakina A, Menclová K, Pudil J, et al. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. World J Gastroenterol. 2019;25:6939–48.

PubMed  PubMed Central  Google Scholar 

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92.

PubMed  PubMed Central  Google Scholar 

Kotaka M, Shirasu H, Watanabe J, Yamazaki K, Hirata K, Akazawa N, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol. 2022;40:9.

Google Scholar 

Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915–20.

CAS  PubMed  PubMed Central